The First Asian, Single-Center Experience of Blastocyst Preimplantation Genetic Diagnosis with HLA Matching in Thailand for the Prevention of Thalassemia and Subsequent Curative Hematopoietic Stem Cell Transplantation of Twelve Affected Siblings

Table 1

Demographics of patients that underwent PGD and PGD-HLA for thalassemia.

	α-Thalassemia	α-Thalassemia-HLA	β-Thalassemia	β-Thalassemia-HLA	Total
Patients	46	2	42	48	138
Stimulation cycles
Total	57	2	60	102	221
Cycle number^a	1 (1-1)	1 (n/a)	1 (1-2)	2 (1-3)	1 (1-2)
Age^a
Maternal	34.3 (30.3-37.1)	34.1 (n/a)	33.6 (31.3-36.6)	33.8 (30.9-36.6)	34.0 (30.9-36.7)
Paternal	36.1 (32.1-40.6)	39.0 (n/a)	35.7 (33.4-39.3)	36.5 (33.8-40.7)	36.3 (33.3-40.0)
Genetic status^b
Carrier/carrier	51	2	59	93	205
Affected/carrier	6	0	1	9	16
Country
Southeast Asia
Thailand	16	1	26	17	60
Vietnam	6	1	3	3	13
Cambodia	1	—	—	3	4
Malaysia	—	—	—	4	4
Laos	1	—	—	—	1
South Asia
India	—	—	4	15	19
Maldives	—	—	2	—	2
Nepal	—	—	—	1	1
East Asia
China	22	—	7	3	32
Other
UAE	—	—	—	2	2

^aMedian (IQR). ^bAlpha-thalassemia carriers are either silent carriers or those with α-thalassemia trait. Live-born alpha-thalassemia-affected patients are those with HbH disease. Beta-thalassemia carriers are silent carriers, those with the thalassemia minor trait, or homozygous for the HbE allele. Beta-thalassemia-affected patients are those with thalassemia major, thalassemia intermedia, or HbE/β-thalassemia.